During the past decade, NCL Institute Neuroscience conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "NCL Institute Neuroscience" are "Multiple Sclerosis" (3 trials) and "Relapsing Multiple Sclerosis" (1 trials). Many other conditions were trialed in "NCL Institute Neuroscience" in a lesser frequency.

Most popular intervention types in "NCL Institute Neuroscience" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Mavenclad®" (2 trials), "Antihistamine" (1 trials), "Fenebrutinib" (1 trials), "Methylprednisolone" (1 trials) and "Ocrelizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "NCL Institute Neuroscience" are 4 trials for "All" genders.

Currently, there are NaN active trials in "NCL Institute Neuroscience". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in NCL Institute Neuroscience, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in NCL Institute Neuroscience, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".